Nina Harmening
Experimental Ophthalmology
University of Geneva
Dr. rer. nat. Nina Harmening, PhD in biology, joined Prof. Thumann’s research group in 2009. She has extensive experience in the isolation and culture of primary cells and cell lines, non-viral gene delivery methodologies including electroporation, the use of the Sleeping Beauty transposon system, and molecular and biochemical analyses. She has been trained in GMP-compliant production of GTMPs (Gene Therapy Medicinal Product) for use in clinical trials, qualified to work under GMP-grade conditions and is the responsible person for production. Currently, she is working on the improvement of the safety profile of SB100X transfected cells.
Engineering of PEDF-Expressing Primary Pigment Epithelial Cells by the SB Transposon System Delivered by pFAR4 Plasmids.
Molecular therapy. Nucleic acids Mar, 2017 | Pubmed ID: 28325297
The Antibiotic-free pFAR4 Vector Paired with the Sleeping Beauty Transposon System Mediates Efficient Transgene Delivery in Human Cells.
Molecular therapy. Nucleic acids , | Pubmed ID: 29858090
Electroporation-Based Genetic Modification of Primary Human Pigment Epithelial Cells Using the Sleeping Beauty Transposon System
Sandra Johnen1,
Nina Harmening2,3,
Corinne Marie4,5,
Daniel Scherman4,
Zsuzsanna Izsvák6,
Zoltán Ivics7,
Peter Walter1,
Gabriele Thumann2,3
1Department of Ophthalmology, University Hospital RWTH Aachen,
2Experimental Ophthalmology, University of Geneva,
3Department of Ophthalmology, University Hospitals of Geneva,
4, Université de Paris, CNRS, INSERM, UTCBS, Unité des technologies Chimiques et Biologiques pour la Santé,
5Chimie ParisTech, PSL Research University,
6, Max Delbrück Center for Molecular Medicine in the Helmholtz Association,
7Division of Medical Biotechnology, Paul-Ehrlich-Institute
关于 JoVE
版权所属 © 2024 MyJoVE 公司版权所有，本公司不涉及任何医疗业务和医疗服务。